The FDA Tracker is a feature of Amino Axiom, a free research information and tracking platform. It records the current regulatory status of research compounds, showing how a compound is classified rather than what it does biologically. It lives at Amino Axiom FDA Tracker. It is a reference feature only.
The platform also hosts a compound library, a glossary, a vendor directory and articles. This walkthrough covers what a status tracker holds, how a researcher in longevity, redox and cellular aging might read it, and where it should not be relied on. It does not describe use of any compound.
Regulatory status is a different axis from the science, and the tracker keeps it separate. Two compounds can have similar published literature and very different classifications, and a classification can change without any change in the underlying biology. A researcher who plans a project around a compound benefits from knowing where it stands before ordering materials or writing a protocol for an institutional review.
What does a regulatory-status view put in front of a researcher?
A regulatory-status view answers a narrow set of questions about a compound: whether it has been the subject of a notice, which category it falls into, and how recently that category changed. Each answer is read together with the compound's identity and the date attached to the entry.
A status tracker answers a narrow set of questions. Has a compound been the subject of a regulatory action or notice? Does it fall into a defined category, such as an approved active ingredient, a substance under review, or a material with no formal standing? Is that category stable or has it moved recently?
Reading such a view is mostly a matter of keeping three labels apart. The first is the compound's identity, meaning its name, formula and registry number. The second is its category in the regulatory sense. The third is the date or context attached to that category. A status without a date is hard to interpret, because categories are revised and a stale entry can mislead.
The Ever Vital catalog lists structural identifiers that make the first label easy to confirm. NAD+ is listed with the formula C21H27N7O14P2, a molecular weight of 663.43 g/mol (anhydrous free acid) and CAS 53-84-9. MOTS-c is listed with the formula C100H152N28O22S2, a molecular weight of 2174.59 g/mol and CAS 1627580-64-6. SS-31 is listed with the formula C32H49N9O5, a molecular weight of 639.80 g/mol and CAS 736992-21-5. Matching a tracker entry to the right registry number is the first check, because compound names are used loosely and a status attached to the wrong molecule is worse than no status.
How does a researcher read the entry for NAD+?
NAD+ is a coenzyme that appears in nearly every metabolic pathway and is studied in cellular aging models alongside sirtuin pathway activity and mitochondrial function. It is also a compound that exists in several contexts at once: as an endogenous cofactor, as a research reagent, and as a component of precursor and related-molecule literature.
That breadth is the reason a status view needs careful reading. A classification that applies to a related molecule, for example a precursor, does not automatically apply to NAD+ itself, and the reverse is also true. The registry number is what keeps the entries straight. A researcher comparing statuses across the NAD family should confirm each entry's number before drawing a conclusion.
The tracker does not change what the published literature says about redox balance or the coenzyme's role in aging models. It adds one more fact to the file for the compound, and that fact is relevant to procurement paperwork, institutional approvals and how a research plan is documented.
What does the entry for MOTS-c illustrate?
MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome and studied as a retrograde mitochondrial signal in cell models. It is a relatively recent entrant to the literature compared with long-established cofactors. That has a practical consequence for status information: newer research compounds are more likely to have no formal classification at all, or to be described in terms of the research-use framework rather than any approval pathway.
A reader should treat the absence of a notice differently from the presence of an approval. The first means that no formal determination is recorded. It does not mean the compound has been assessed and cleared. A tracker that makes this distinction visible, by showing what is on record and what is not, helps keep a literature review honest.
For a researcher in the longevity lane the useful question is not whether a status looks favorable. It is whether the status is documented, current and attached to the right molecule, so that the research plan can cite it accurately.
What can a status entry tell a researcher about SS-31?
SS-31 is a short synthetic tetrapeptide described in published structural analyses as targeting cardiolipin on the inner mitochondrial membrane. It is a useful example because it is discussed in the literature under more than one name, and because some compounds in this class have a history of clinical-stage development, which can attach regulatory records to one name and not another.
Reading its tracker entry is therefore an exercise in matching names. A status recorded under a nonproprietary or development name belongs to the molecule only if the structure matches. A researcher can verify that against the formula and registry number in the supplier catalog. If the entry and the catalog disagree on identity, the right response is to stop and look at the original source rather than assume they refer to the same material.
What are the limits of a status tracker?
A tracker is a reading aid, and several cautions apply.
First, it is a secondary summary. The authoritative record is the one maintained by the regulator, and any decision that depends on a status, such as an institutional submission, should cite the primary notice and its date.
Second, status changes. A tracker can be accurate on the day an entry was written and out of date a month later. The date attached to an entry matters as much as its content.
Third, status is not evidence about biology. A classification says nothing about whether a compound's reported effects in a cell model are robust or replicable. Those judgments come from the primary literature.
Fourth, entries describe research context only. Nothing in the tracker, or in this article, speaks to use outside the laboratory, and none of these compounds is intended for human use. Researchers remain responsible for compliance with all applicable regulations in their jurisdiction.
How can the tracker fit into a research workflow?
A longevity researcher can read a tracker entry in four steps, with identity checked before status and the date noted every time. The routine below is a documentation habit for planning, nothing more.
Start from the scientific question and a shortlist of compounds.
Confirm each compound's identity against the catalog formula and registry number.
Open the tracker entry for each, note the category and its date, and flag any entry that is missing, old or attached to a differently named molecule.
Record the status and its source in the project file, so a later reviewer can see what was known at planning time.
Used this way, the FDA Tracker does one narrow job: it keeps the regulatory facts about a compound next to its identity, so that the paperwork side of a longevity project is checked early and on the record.
This article is provided for informational and research purposes only. The compounds discussed are research chemicals intended for laboratory use only. They are not drugs, supplements or food, and are not intended to diagnose, treat, cure or prevent any disease. Ever Vital does not sell products intended for human use. Researchers are responsible for compliance with all applicable local, state and federal regulations.
Reference
Common questions
The Amino Axiom FDA Tracker shows the current regulatory classification of research compounds, such as an approved active ingredient, a substance under review, or a material with no formal standing. It records status, not biology. A status is only meaningful alongside its date and the compound's registry number, so both should be read together.
No. A missing notice means no formal determination is recorded for that compound, which is different from an assessment or approval. Newer research compounds are especially likely to have no classification. A tracker that shows what is on record and what is not keeps a literature review honest.
A registry number ties a status to a specific molecule. Compounds are discussed under several names, and a status recorded under a development or nonproprietary name belongs to the material only if the structure matches. Checking the formula and CAS number against the catalog prevents attaching a status to the wrong compound.
A tracker is a secondary summary and can be accurate on the day an entry was written and outdated a month later. The date attached to an entry matters as much as its content. For any institutional submission, cite the regulator's primary notice and its date rather than the tracker alone.
Join the list.
Restock alerts, subscriber discounts, and first access to new compound drops.
